|

BeijngFH Health Cohort Study

RECRUITINGSponsored by Beijing Friendship Hospital
Actively Recruiting
SponsorBeijing Friendship Hospital
Started2022-04-18
Est. completion2032-04-18
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Metabolic associated fatty liver disease(MEFLD) is a major chronic liver disease that can lead to various adverse events, such as liver cancer, cardiovascular disease, and chronic kidney disease. The present community-based cohort study enrolls subjects who take health physical examinations at the sub-center outpatient department, Beijing Friendship Hospital. Investigators collect their baseline information, including demographic data, clinical history, physical examination, laboratory results, imageological examination, and so on. Follow-up surveys are conducted annually and the information collected is the same as the baseline. The outcome information, including cardiovascular disease, malignancy, liver cirrhosis, liver decompensation, liver transplantation, and all-cause mortality, are obtained by linking to the hospital discharge database and death registration system of Beijing. The primary aim of the study is to build a risk-stratified evaluation system for MAFLD through the cohort.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Aged 18 years or older
* Permanent residents in Beijing
* Signing informed consent

Exclusion Criteria:

* No

Conditions2

Liver DiseaseNon Alcoholic Fatty Liver Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.